Study | Design | Pregnancies (n) | No. of pregnancies in infliximab-exposed group | No. of pregnancies in adalimumab-exposed group | Study quality |
---|---|---|---|---|---|
Kiely CJ [17] | P | 21 | 10 Infliximab | 11 Adalimumab | ☆☆☆☆☆☆ |
Schnitzler F [18] | P | 42 | 35 Infliximab | 7 Adalimumab | ☆☆☆☆☆☆☆ |
Seirafi M [19] | P + R | 128 | 86 Infliximab | 42 Adalimumab | ☆☆☆☆☆☆☆ |
Casanova MJ [20] | R | 29 | 20 Infliximab | 9 Adalimumab | ☆☆☆☆☆☆☆ |
Julsgaard M [21] | P | 80 | 44 Infliximab | 36 Adalimumab | ☆☆☆☆☆☆ |
Arsenescu R [22] | R | 10 | 8 Infliximab | 2 Adalimumab | ☆☆☆☆☆ |
Slama W [23] | P | 186 | 122 Infliximab | 64 Adalimumab | ☆☆☆☆☆ |
Zelinkova Z [24] | P + R | 31 | 18 Infliximab | 13 Adalimumab | ☆☆☆☆☆☆ |